B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses (Q56897632)

2

0 references

Marie-Lyse Gougeon

3

0 references

Serge Jacquot

4

0 references

Brigitte Lemercier

5

0 references

Annick Lim

6

0 references

Danièle Gilbert

7

0 references

Ingrid Dutot

8

0 references

Jean C Roujeau

9

0 references

Michel D'Incan

10

0 references

Christophe Bedane

11

0 references

François Tron

12

0 references

Pascal Joly

Journal of Investigative Dermatology

13

0 references

language of work or name

English

0 references

publication date

December 2008

0 references

published in

0 references

volume

128

0 references

issue

12

0 references

page(s)

2859-69

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/jid.2008.178

0 references

cites work

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Peripheral development of B cells in mouse and man.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

CHOP plus rituximab--balancing facts and opinion

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

T cell control in autoimmune bullous skin disorders

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Rituximab for pemphigus vulgaris.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

A single cycle of rituximab for the treatment of severe pemphigus.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Pemphigus and pemphigoid. A review of the advances made since 1964.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Many human peripheral VH5-expressing IgM+ B cells display a unique heavy-chain rearrangement

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Treatment of SLE with anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Pemphigus: autoimmune diseases of keratinocyte's adhesion molecules

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Identification and characterization of circulating human transitional B cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.178

7 January 2021